The US Food & Drug Administration’s 29 June approval of another new indication for Merck’s blockbuster anti-PD-1 cancer treatment Keytruda (permbrolizumab) is all too easy to overlook.
Amid the COVID-19 pandemic, the extension of the Keytruda label to yet another cancer type – in this case, patients...






